LYMPHOMA, T-CELL, PERIPHERAL
Clinical trials for LYMPHOMA, T-CELL, PERIPHERAL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL, PERIPHERAL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, PERIPHERAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancer: targeted drug soquelitinib faces standard care in phase 3 trial
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard treatments for people with certain types of T-cell lymphoma that have come back or not responded to therapy. About 150 adults will be randomly assigned to receive either soquelitinib or a standard single-agent chemo…
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 08:53 UTC
-
New hope for rare blood cancer: drug duo aims to keep lymphoma in check
Disease control Recruiting nowThis study tests whether adding the drug tucidinostat to standard chemotherapy (CHOP) can help people with a rare type of lymphoma (PTCL-TFH) live longer without their cancer getting worse. About 224 adults with newly diagnosed disease will be randomly assigned to get either tuci…
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated May 08, 2026 12:01 UTC